Behavioral Neurobiology of Schizophrenia and Its Treatment by Neal R. Swerdlow

By Neal R. Swerdlow

This ebook describes the cutting-edge of therapy of schizophrenia and displays its improvement in 22 chapters written by means of top gurus within the box

Show description

Read or Download Behavioral Neurobiology of Schizophrenia and Its Treatment (Current Topics in Behavioral Neurosciences, Volume 4) PDF

Best biophysics books

The Nile: Origin, environments, limnology and human use (Monographiae Biologicae)

What have we learnt in regards to the Nile because the mid-1970s, the instant whilst Julian Rzóska determined that the time had come to post a entire quantity in regards to the biology, and the geological and cultural background of that fab river? And what alterations have in the meantime happened within the basin? The human popu- tion has greater than doubled, in particular in Egypt, but additionally in East Africa.

Erythropoietins and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology (Milestones in Drug Therapy)

A entire one-source advisor to the most up-tp-date details on crimson blood mobilephone formation and the motion of recombinant human erythropoietins. subject matters coated comprise: erythropoiesis, recombinant protein discovery and creation, and remedy of sufferers with anemia. the latest theories in erythropoiesis (receptors, signaling), production, new formulations, and medical learn are mentioned.

Additional resources for Behavioral Neurobiology of Schizophrenia and Its Treatment (Current Topics in Behavioral Neurosciences, Volume 4)

Sample text

26 The Cardiovascular and Metabolic Risk Profile of Subjects Entering the CATIE Schizophrenia Trial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 4 The Impact of Antipsychotic Treatment on Cardiovascular and Metabolic Outcomes in the CATIE Schizophrenia Trial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Metabolic Outcomes . . . . . . . . . . . . . . . . . . . .

Annu Rev Neurosci 24:167 202 Moseley AM, Lanzarone S, Bosman JM, van Loo MA, de Bie RA, Hassett L, Caplan B (2004) Ecological validity of walking speed assessment after traumatic brain injury: a pilot study. J Head Trauma Rehabil 19:341 348 Murray CL, Lopez AD (1996) The global burden of disease. Harvard University Press, Cambridge, MA Naber D, Karow A (2001) Good tolerability equals good results: the patient’s perspective. Eur Neuropsychopharmacol 11(Suppl 4):S391 S396 Nakagami E, Xie B, Hoe M, Brekke JS (2008) Intrinsic motivation, neurocognition and psycho social functioning in schizophrenia: testing mediator and moderator effects.

2 Hypotheses on Schizophrenia and Metabolic Risk, and Adiposity Independent Drug Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Abstract Schizophrenia patients have high prevalence of cardiovascular (CV) disease risk factors and high CV mortality, with increasing concern over the contribution of antipsychotic medications to cardiometabolic risk.

Download PDF sample

Rated 4.51 of 5 – based on 23 votes